Legacy Advisors’s ImmunityBio IBRX Stock Holding History

Legacy Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,500	Closed	-$79K	–	383
2024 Q2	$79K	Hold	12,500	–	–	0.01%	324
2024 Q1	$67.1K	Hold	12,500	–	–	0.01%	310
2023 Q4	$62.8K	Hold	12,500	–	–	0.01%	302
2023 Q3	$21.1K	Buy	+12,500	New	+$25.1K	﹤0.01%	280

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Legacy Advisors's IBRX Position: Q3 2024 in Review

Legacy Advisors sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 12,500 shares — an estimated $79K sold.

Legacy Advisors first reported a position in IBRX in Q3 2023 and held it in 4 quarters. The position peaked at $79K in Q2 2024. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

Legacy Advisors reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
Legacy Advisors sold 12,500 ImmunityBio shares in Q3 2024, an estimated $79K.
Legacy Advisors first reported a position in ImmunityBio in Q3 2023 and held it in 4 quarters.
Legacy Advisors's ImmunityBio position peaked at $79K in Q2 2024.
181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Legacy Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.